Tweet
Shares of NeoGenomics, Inc. (NASDAQ:NEO) have earned a consensus rating of "Buy" from the twelve brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $17.50.
NEO has been the topic of a number of recent analyst reports. Zacks Investment Research lowered shares of NeoGenomics from a "hold" rating to a "sell" rating in a research note on Thursday, July 19th. ValuEngine upgraded shares of NeoGenomics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 17th. BidaskClub upgraded shares of NeoGenomics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, April 28th. BTIG Research restated a "buy" rating and set a $15.00 price target on shares of NeoGenomics in a research note on Thursday, June 21st. Finally, First Analysis lowered shares of NeoGenomics from an "overweight" rating to an "equal weight" rating and set a $11.00 price target on the stock. in a research note on Wednesday, May 2nd. Get NeoGenomics alerts:
In other news, insider Steven C. Jones sold 169,467 shares of the stock in a transaction on Thursday, May 31st. The shares were sold at an average price of $11.68, for a total value of $1,979,374.56. Following the sale, the insider now owns 234,918 shares in the company, valued at $2,743,842.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink . Also, insider Steven C. Jones sold 203,500 shares of the stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $14.00, for a total transaction of $2,849,000.00. Following the completion of the sale, the insider now owns 241,815 shares in the company, valued at approximately $3,385,410. The disclosure for this sale can be found here . Insiders sold 861,808 shares of company stock worth $11,135,863 in the last quarter. Company insiders own 12.20% of the company's stock. Several large investors have recently added to or reduced their stakes in NEO. Wells Fargo & Company MN boosted its holdings in NeoGenomics by 25.3% during the fourth quarter. Wells Fargo & Company MN now owns 112,039 shares of the medical research company's stock worth $992,000 after buying an additional 22,647 shares in the last quarter. Geode Capital Management LLC boosted its holdings in NeoGenomics by 5.7% during the fourth quarter. Geode Capital Management LLC now owns 512,281 shares of the medical research company's stock worth $4,538,000 after buying an additional 27,429 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in NeoGenomics by 37.8% during the fourth quarter. Alliancebernstein L.P. now owns 62,700 shares of the medical research company's stock worth $556,000 after buying an additional 17,200 shares in the last quarter. Deutsche Bank AG boosted its holdings in NeoGenomics by 121.8% during the fourth quarter. Deutsche Bank AG now owns 136,675 shares of the medical research company's stock worth $1,208,000 after buying an additional 75,048 shares in the last quarter. Finally, Guggenheim Capital LLC boosted its holdings in NeoGenomics by 46.6% during the fourth quarter. Guggenheim Capital LLC now owns 39,457 shares of the medical research company's stock worth $351,000 after buying an additional 12,538 shares in the last quarter. Hedge funds and other institutional investors own 83.65% of the company's stock.
Shares of NeoGenomics stock opened at $12.55 on Tuesday. The company has a current ratio of 1.74, a quick ratio of 1.59 and a debt-to-equity ratio of 0.77. NeoGenomics has a 12-month low of $7.08 and a 12-month high of $15.00. The company has a market cap of $1.02 billion, a price-to-earnings ratio of 209.17, a P/E/G ratio of 6.94 and a beta of 0.83.
NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, July 24th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.04 by $0.01. NeoGenomics had a negative net margin of 0.98% and a negative return on equity of 0.36%. The business had revenue of $67.70 million for the quarter, compared to analyst estimates of $66.40 million. During the same quarter in the prior year, the business posted $0.04 EPS. NeoGenomics's revenue for the quarter was up 8.7% compared to the same quarter last year. research analysts forecast that NeoGenomics will post 0.09 EPS for the current year.
NeoGenomics Company Profile
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories